10x Genomics reports Third Quarter 2026 Financial Results. Nov 05, 2026, 16:05 ET PLEASANTON, Calif., Nov. 5, 2026 /PRNewswire/ - 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the third quarter ended September 30, 2026. Recent Updates * Revenue was $150.7 million for the third quarter of 2026, representing a 1% increase over the corresponding period of 2025. * Began global commercial shipments of Atera, with extraordinary early demand translating into ambitious new research programs spanning discovery, translational and biopharma research. * Introduced Sentira, a cloud analysis platform to help customers turn complex biological datasets into insights, powered by NVIDIA accelerated computing for spatial data processing and Anthropic's Claude for agentic AI analysis of single cell data. "The biggest highlight of the quarter was the start of commercial shipments of Atera. Enthusiasm for the platform has continued to build, and we are incredibly excited to be putting instruments in customers' hands. We were also encouraged with the results across our broader business, driven by continued strength in consumables," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "As biology is entering a new era of AI and data maximalism, 10x is positioned incredibly well to benefit and to be the key enabler of progress going forward." Third Quarter 2026 Financial Results Revenue was $150.7 million for the third quarter of 2026, as compared to $149.0 million for the corresponding period of 2025. Revenue increased 1% over the corresponding period of 2025. Gross margin was 75% for the third quarter of 2026, as compared to 67% for the corresponding prior year period. The increase in gross margin was primarily due to lower inventory write-downs and changes in product mix. Operating expenses were $129.0 million for the third quarter of 2026, a 3% decrease from $132.5 million for the corresponding prior year period. The decrease was primarily driven by lower personnel and lab equipment expenses, partially offset by higher litigation expenses. Operating loss was $16.1 million for the third quarter of 2026, as compared to operating loss of $32.2 million for the corresponding prior year period. Net loss was $19.4 million for the third quarter of 2026, as compared to net loss of $27.5 million for the corresponding prior year period. Cash and cash equivalents and marketable securities were $575.7 million as of September 30, 2026. 2026 Financial Guidance 10x Genomics is raising its full year 2026 revenue guidance and now expects revenue in the range of $625 million to $635 million, versus the previous range of $610 million to $630 million. Excluding the non-recurring license and royalty revenue related to patent litigation settlements in both 2026 and 2025, this represents 4% to 6% growth over full year 2025. Webcast and Conference Call Information 10x Genomics will host a conference call to discuss the third quarter 2026 financial results, business developments and outlook after market close on Thursday, November 5, 2026 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay at least 45 days after the event. About 10x Genomics 10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "outlook," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s products, services, business strategy, collaborations and opportunities; the commercial launch of, demand for and customer adoption of Atera; the capabilities, availability and expected benefits of Sentira, including its use of third-party accelerated computing and artificial intelligence technologies; the role of artificial intelligence in advancing biological research and 10x Genomics, Inc.'s ability to benefit from that trend; continued demand for consumables; and 10x Genomics, Inc.'s financial performance and results of operations, including expectations regarding revenue, revenue growth and guidance. These statements are based on management's current expectations, forecasts, beliefs, estimates, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2025 filed on February 12, 2026 and the company's quarterly report on Form 10-Q for the quarter ended September 30, 2026 to be filed with the U.S. Securities and Exchange Commission ("SEC"), and elsewhere in the documents 10x Genomics, Inc. files with the SEC from time to time. Disclosure Information 10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. | 10x Genomics, Inc. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share data) | | / | Three Months Ended September 30, | / | Nine Months Ended September 30, | | / | 2026 | / | 2025 | / | 2026 | / | 2025 | | Products and services revenue | $ 150,210 | / | $ 148,019 | / | $ 449,200 | / | $ 430,999 | | License and royalty revenue | 457 | / | 983 | / | 3,346 | / | 45,794 | | Revenue [(1)] | 150,667 | / | 149,002 | / | 452,546 | / | 476,793 | | Cost of products and services revenue [(2)] | 37,740 | / | 48,695 | / | 120,944 | / | 145,957 | | Gross profit | 112,927 | / | 100,307 | / | 331,602 | / | 330,836 | | Operating expenses: | / | / | / | / | / | / | / | | Research and development [(2)] | 52,929 | / | 57,194 | / | 166,567 | / | 182,663 | | Selling, general and administrative [(2)] | 76,055 | / | 75,355 | / | 221,093 | / | 239,517 | | Gain on settlement | - | / | - | / | (3,400) | / | (49,900) | | Total operating expenses | 128,984 | / | 132,549 | / | 384,260 | / | 372,280 | | Loss from operations | (16,057) | / | (32,242) | / | (52,658) | / | (41,444) | | Other income (expense): | / | / | / | / | / | / | / | | Interest income | 5,018 | / | 5,199 | / | 14,829 | / | 13,156 | | Interest expense | - | / | 3 | / | - | / | - | | Other income (expense), net | (7,437) | / | (1,165) | / | (12,139) | / | 3,574 | | Total other income (expense) | (2,419) | / | 4,037 | / | 2,690 | / | 16,730 | | Loss before provision for income taxes | (18,476) | / | (28,205) | / | (49,968) | / | (24,714) | | Provision for (benefit from) income taxes | 949 | / | (733) | / | 858 | / | 2,578 | | Net loss | $ (19,425) | / | $ (27,472) | / | $ (50,826) | / | $ (27,292) | | Net loss per share, basic and diluted | $ (0.15) | / | $ (0.22) | / | $ (0.39) | / | $ (0.22) | | Weighted-average shares used to compute net loss per share, basic and diluted | 130,805,838 | / | 125,502,291 | / | 129,570,736 | / | 123,965,205 | | [(1)] | The following table represents total revenue by source for the periods indicated (in thousands). Spatial includes the Company's Visium, Xenium and Atera products: | | / | / | | / | Three Months Ended September 30, | / | Nine Months Ended September 30, | | / | 2026 | / | 2025 | / | 2026 | / | 2025 | | Instruments | / | / | / | / | / | / | / | | Single Cell | $ 3,782 | / | $ 4,927 | / | $ 12,092 | / | $ 16,567 | | Spatial | 3,076 | / | 7,072 | / | 13,689 | / | 24,744 | | Total instruments revenue | 6,858 | / | 11,999 | / | 25,781 | / | 41,311 | | Consumables | / | / | / | / | / | / | / | | Single Cell | 93,139 | / | 92,519 | / | 270,484 | / | 262,416 | | Spatial | 41,188 | / | 35,373 | / | 124,396 | / | 103,017 | | Total consumables revenue | 134,327 | / | 127,892 | / | 394,880 | / | 365,433 | | Services | 9,025 | / | 8,128 | / | 28,539 | / | 24,255 | | Products and services revenue | 150,210 | / | 148,019 | / | 449,200 | / | 430,999 | | License and royalty revenue | 457 | / | 983 | / | 3,346 | / | 45,794 | | Total revenue | $ 150,667 | / | $ 149,002 | / | $ 452,546 | / | $ 476,793 | | [(1)] | The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): | | / | / | | / | Three Months Ended September 30, | / | Nine Months Ended September 30, | | / | 2026 | / | 2025 | / | 2026 | / | 2025 | | Americas | / | / | / | / | / | / | / | | United States[*] | $ 82,093 | / | $ 77,246 | / | $ 240,895 | / | $ 267,555 | | Americas (excluding United States) | 3,849 | / | 2,625 | / | 10,172 | / | 9,044 | | Total Americas | 85,942 | / | 79,871 | / | 251,067 | / | 276,599 | | Europe, Middle East and Africa | 38,753 | / | 41,624 | / | 115,577 | / | 108,253 | | Asia-Pacific | / | / | / | / | / | / | / | | China | 15,216 | / | 15,189 | / | 46,021 | / | 55,242 | | Asia-Pacific (excluding China) | 10,756 | / | 12,318 | / | 39,881 | / | 36,699 | | Total Asia-Pacific | 25,972 | / | 27,507 | / | 85,902 | / | 91,941 | | Total revenue | $ 150,667 | / | $ 149,002 | / | $ 452,546 | / | $ 476,793 | | * Includes license and royalty revenue. | | [(2)] Includes stock-based compensation expense as follows: | | / | | / | Three Months Ended September 30, | / | Nine Months Ended September 30, | | (in thousands) | 2026 | / | 2025 | / | 2026 | / | 2025 | | Cost of revenue | $ 2,157 | / | $ 2,011 | / | $ 5,911 | / | $ 6,481 | | Research and development | 8,940 | / | 11,318 | / | 30,168 | / | 38,037 | | Selling, general and administrative | 11,999 | / | 11,935 | / | 35,275 | / | 39,067 | | Total stock-based compensation expense | $ 23,096 | / | $ 25,264 | / | $ 71,354 | / | $ 83,585 | | 10x Genomics, Inc. Condensed Consolidated Balance Sheets (Unaudited) (In thousands) | | / | September 30, 2026 | / | December 31, 2025 | | Assets | / | / | / | | Current assets: | / | / | / | | Cash and cash equivalents | $ 526,187 | / | $ 473,966 | | Marketable securities | 49,493 | / | 49,443 | | Accounts receivable, net | 55,701 | / | 47,013 | | Other receivables | 3,055 | / | 35,480 | | Inventory | 64,629 | / | 56,341 | | Prepaid expenses and other current assets | 19,566 | / | 22,208 | | Total current assets | 718,631 | / | 684,451 | | Property and equipment, net | 210,239 | / | 226,711 | | Operating lease right-of-use assets | 54,759 | / | 60,450 | | Goodwill | 6,918 | / | 4,511 | | Intangible assets, net | 58,663 | / | 62,329 | | Other noncurrent assets | 13,919 | / | 2,913 | | Total assets | $ 1,063,129 | / | $ 1,041,365 | | Liabilities and stockholders' equity | / | / | / | | Current liabilities: | / | / | / | | Accounts payable | $ 21,594 | / | $ 12,733 | | Accrued compensation and related benefits | 39,657 | / | 42,500 | | Accrued expenses and other current liabilities | 32,181 | / | 39,971 | | Deferred revenue | 22,956 | / | 23,902 | | Operating lease liabilities | 11,946 | / | 10,985 | | Contingent consideration, current | 12,036 | / | 23,363 | | Total current liabilities | 140,370 | / | 153,454 | | Contingent consideration, noncurrent | 5,842 | / | 1,237 | | Operating lease liabilities, noncurrent | 63,846 | / | 73,376 | | Deferred revenue, noncurrent | 8,530 | / | 10,501 | | Other noncurrent liabilities | 6,505 | / | 6,471 | | Total liabilities | 225,093 | / | 245,039 | | Stockholders' equity: | / | / | / | | Preferred stock | - | / | - | | Common stock | 2 | / | 2 | | Additional paid-in capital | 2,399,254 | / | 2,306,690 | | Accumulated deficit | (1,561,417) | / | (1,510,591) | | Accumulated other comprehensive income | 197 | / | 225 | | Total stockholders' equity | 838,036 | / | 796,326 | | Total liabilities and stockholders' equity | $ 1,063,129 | / | $ 1,041,365 | SOURCE 10x Genomics, Inc.

10x Genomics (NASDAQ:TXG) releases earnings results, beats expectations by $0.12 EPS. November 5, 2026 Key points. * 10x Genomics beat quarterly expectations, reporting adjusted EPS of ($0.15) versus the consensus estimate of ($0.27), and revenue of $150.7 million versus expectations of $148.0 million. * The company raised its 2026 revenue outlook to $625 million-$635 million. Atera shipments began in September, with about 50 instruments now expected to ship by year-end, while spatial consumables revenue grew 16%. * Instrument revenue fell 43%, and management expects gross margin to decline from 75% in the quarter to the low-to-mid 60% range in Q4 as Atera placements weigh on product mix. * Interested in 10x Genomics? Here are five stocks we like better. 10x Genomics (NASDAQ:TXG - Get Free Report) announced its earnings results on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.12, FiscalAI reports. 10x Genomics had a negative return on equity of 9.33% and a negative net margin of 12.18%. The business had revenue of $150.67 million for the quarter, compared to analysts' expectations of $147.96 million. Here are the key takeaways from 10x Genomics' conference call: * Third-quarter revenue was $150.7 million, up 1% year over year, and 10X raised its 2026 revenue outlook to $625 million-$635 million. Excluding patent-litigation settlement revenue, the range implies 4%-6% growth over 2025. * Atera commercial shipments began in September, and the company now expects to ship about 50 instruments by year-end, up from its prior estimate of 40. Management cited strong demand, while noting that production, installation, and customer training - not orders - are limiting the pace of rollout. * Spatial consumables revenue grew 16%, with strong Xenium demand; management expects double-digit spatial consumables growth in Q4 as Atera consumables shipments begin. It said customer interest in Atera's whole-transcriptome option has exceeded expectations. * Instrument revenue fell 43% as sales of Chromium, Visium, and Xenium instruments declined, partly reflecting customers waiting for Atera. Gross margin was 75% in Q3, but management expects it to fall to the low-to-mid 60% range in Q4 and to be lower in 2027 as Atera placements make the mix more instrument-heavy. * Single-cell reaction volumes grew at a double-digit rate, supported by Flex Apex adoption, but single-cell consumables revenue rose only 1%. Management said the lower price per reaction for Apex is weighing on revenue as customers shift toward the platform. 10x Genomics stock performance. Shares of TXG stock traded down $9.46 during trading hours on Thursday, reaching $58.06. The company had a trading volume of 5,954,404 shares, compared to its average volume of 3,028,884. The company has a market capitalization of $7.56 billion, a P/E ratio of -98.41 and a beta of 2.03. The stock's fifty day simple moving average is $74.19 and its 200 day simple moving average is $41.22. 10x Genomics has a twelve month low of $12.80 and a twelve month high of $102.81. Insider activity at 10x Genomics. In other news, Director Shehnaaz Suliman sold 5,723 shares of the company's stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $81.19, for a total value of $464,650.37. Following the sale, the director owned 23,792 shares in the company, valued at approximately $1,931,672.48. This represents a 19.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Benjamin Hindson sold 13,818 shares of the business's stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $63.02, for a total value of $870,810.36. Following the transaction, the insider owned 488,182 shares of the company's stock, valued at $30,765,229.64. This represents a 2.75% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 179,333 shares of company stock worth $11,810,070. 8.84% of the stock is currently owned by insiders. Analyst ratings changes. Several brokerages have recently commented on TXG. Citigroup upped their price objective on shares of 10x Genomics from $45.00 to $50.00 and gave the stock a "neutral" rating in a report on Friday, August 7th. Barclays lifted their price objective on shares of 10x Genomics from $52.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, October 7th. Stifel Nicolaus set a $70.00 price target on 10x Genomics in a research note on Tuesday, October 13th. Piper Sandler increased their target price on shares of 10x Genomics from $47.00 to $80.00 and gave the company a "neutral" rating in a report on Monday, September 28th. Finally, Argus began coverage on shares of 10x Genomics in a report on Monday, September 28th. They set a "buy" rating and a $110.00 target price for the company. Five equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, 10x Genomics presently has an average rating of "Hold" and a consensus target price of $68.00. Discover more Invest in Stocks Start Investing Stock Average Calculator 10x Genomics company profile. 10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods. The company's product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider 10x Genomics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list. While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power. Continue following MarketBeat

10x Genomics has launched Sentira Single Cell, a cloud-based AI application built on Anthropic's Claude. Researchers can use plain language to analyse Chromium single cell data. The company also appointed Ansuman Satpathy and Joseph Gilliam to its board. Satpathy has genomics, immunology and AI drug discovery experience; Gilliam brings public company operating and capital markets experience. Third-quarter earnings are due Thursday. Analysts project revenue of $808.4 million and earnings of $133.3 million by 2029, up from a loss of $75.1 million now, with 9.4% yearly revenue growth. The most cautious analysts expect $734.4 million in revenue and $119.8 million in earnings. Funding pressure on research customers and pricing pressure remain key risks.